Article
Clinical Neurology
Alexis Moscoso, Michel J. Grothe, Nicholas J. Ashton, Thomas K. Karikari, Juan Lantero Rodriguez, Anniina Snellman, Marc Suarez-Calvet, Henrik Zetterberg, Kaj Blennow, Michael Scholl
Summary: Measurement of tau phosphorylated at threonine 181 (p-tau181) in blood plasma is proposed as a specific biomarker for Alzheimer's disease. Longitudinal study reveals that plasma p-tau181 increases before amyloid-beta markers reach abnormal levels, correlating with amyloid-beta pathology. Plasma p-tau181 also shows associations with widespread cortical tau aggregation and may be a useful diagnostic and screening tool for Alzheimer's disease.
Article
Medicine, General & Internal
Nicholas J. Ashton, Andrea L. Benedet, Tharick A. Pascoal, Thomas K. Karikari, Juan Lantero-Rodriguez, Wagner S. Brum, Sulantha Mathotaarachchi, Joseph Therriault, Melissa Savard, Mira Chamoun, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Serge Gauthier, Eduardo R. Zimmer, Henrik Zetterberg, Kaj Blennow, Pedro Rosa-Neto
Summary: CSF p-tau epitopes increase early in the development of AD pathology and are a primary candidate for detecting incipient Aβ pathology.
Article
Clinical Neurology
William Charles Kreisl, Patrick J. Lao, Aubrey Johnson, Zeljko Tomljanovic, Julia Klein, Krista Polly, Benjamin Maas, Krystal K. Laing, Anthony G. Chesebro, Kay Igwe, Qolamreza R. Razlighi, Lawrence S. Honig, Xinyu Yan, Seonjoo Lee, Akiva Mintz, Jose A. Luchsinger, Yaakov Stern, D. P. Devanand, Adam M. Brickman
Summary: F-18-MK-6240 showed good correlation with CSF tau and p-tau levels, as well as age, cognition, and amyloid-based AD biomarkers. The study also found that F-18-MK-6240 binding patterns were associated with specific cognitive impairments in amyloid-positive participants, reflecting the progression of AD pathology.
ALZHEIMERS & DEMENTIA
(2022)
Article
Clinical Neurology
Zhi-Bo Wang, Lan Tan, Hui-Fu Wang, Shi-Dong Chen, Yan Fu, Pei-Yang Gao, Ya-Hui Ma, Yu Guo, Jia-Hui Hou, Dan-Dan Zhang, Jin-Tai Yu
Summary: This study aimed to assess the accuracy of biomarkers related to amyloid, tau, and neurodegeneration in predicting Alzheimer's disease (AD) neuropathology at different clinical stages. The results showed that amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) amyloid beta (Aβ)42/phosphorylated tau (p-tau)181 performed well in differentiating AD and predicting neuropathological changes in early and late clinical stages. However, CSF Aβ42 performed better in early clinical stage, while CSF p-tau181, CSF t-tau, and plasma p-tau181 performed better in late clinical stage.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Wha Jin Lee, Hanna Cho, Min Seok Baek, Han-Kyeol Kim, Jae Hoon Lee, Young Hoon Ryu, Chul Hyoung Lyoo, Joon-Kyung Seong
Summary: This study describes the differences in tau-spreading processes in early- and late-onset Alzheimer's disease spectrum. The results suggest that the tau propagation pathways are distinct between individuals with early and late onset of symptoms, with specific hub regions playing a dominant role in tau spreading.
ALZHEIMERS RESEARCH & THERAPY
(2022)
Article
Clinical Neurology
Anna Steward, Davina Biel, Matthias Brendel, Anna Dewenter, Sebastian Roemer, Anna Rubinski, Ying Luan, Martin Dichgans, Michael Ewers, Nicolai Franzmeier
Summary: This study found that lower network segregation is associated with accelerated cognitive decline in Alzheimer's disease. Furthermore, the degree of network segregation is related to the speed of tau protein spreading in the brain.
ALZHEIMERS & DEMENTIA
(2023)
Article
Medicine, General & Internal
Cecile Tissot, Joseph Therriault, Peter Kunach, Andrea L. Benedet, Tharick A. Pascoal, Nicholas J. Ashton, Thomas K. Karikari, Stijn Servaes, Firoza Z. Lussier, Mira Chamoun, Dana L. Tudorascu, Jenna Stevenson, Nesrine Rahmouni, Nina Margherita Poltronetti, Vanessa Pallen, Gleb Bezgin, Min Su Kang, Sulantha S. Mathotaarachchi, Yi-Ting Wang, Jaime Fernandez Arias, Pamela Cristina Lukasewicz Ferreira, Joao Pedro Ferrari-Souza, Eugeen Vanmechelen, Kaj Blennow, Henrik Zetterberg, Serge Gauthier, Pedro Rosa-Neto
Summary: This study investigated the agreement between [F-18]MK6240 tau-PET, plasma pTau181, and pTau231 in Alzheimer's disease. The findings suggest that these biomarkers reflect different stages of tau progression and can be useful in diagnosing and evaluating the disease stage.
Article
Neurosciences
Charles D. Chen, Maria Rosana Ponisio, Jordan A. Lang, Shaney Flores, Suzanne E. Schindler, Anne M. Fagan, John C. Morris, Tammie L. S. Benzinger
Summary: F-18-flortaucipir PET was approved by FDA for visualizing neurofibrillary tangles in the brains of patients with cognitive impairment. Visual interpretation was found to be consistent with SUVR and moderately consistent with CSF biomarkers. However, it could not predict the clinical assessment in some cases.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Clinical Neurology
Marina Tedeschi Dauar, Anne Labonte, Cynthia Picard, Justin Miron, Pedro Rosa-Neto, Henrik Zetterberg, Kaj Blennow, Sylvia Villeneuve, Judes Poirier
Summary: This study investigates the role of the CNTN5 rs1461684 G variant and contactin 5 protein in sporadic Alzheimer's disease (sAD). The findings show that CSF contactin 5 levels increase in cognitively unimpaired individuals but decrease in mild cognitive impairment and sAD. CSF contactin 5 is correlated with sAD biomarkers and synaptic markers. The rs1461684 G variant is associated with faster disease progression in cognitively unimpaired subjects. Decreased CNTN5 mRNA levels are observed in the presence of the G allele and as a function of Alzheimer's disease stages. These results highlight the significance of the rs1461684 G variant, contactin 5 protein, and mRNA in the early stages of sAD.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Laura Nisenbaum, Robert Martone, Tianle Chen, Rajasimhan Rajagovindan, Gersham Dent, John Beaver, Carrie Rubel, Annie Racine, Ping He, Katie Harrison, Robert Dean, Manu Vandijck, Samantha Budd Haeberlein
Summary: This study assessed the use of cerebrospinal fluid (CSF) biomarkers as an alternative to positron emission tomography (PET) for confirming brain amyloid beta (A beta) pathology. The results showed a robust concordance between CSF biomarkers and amyloid PET, and the ratios of CSF biomarkers exhibited higher diagnostic accuracy for A beta pathology confirmation.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Olin Janssen, Willemijn J. Jansen, Stephanie J. B. Vos, Merce Boada, Lucilla Parnetti, Tomasz Gabryelewicz, Tormod Fladby, Jose Luis Molinuevo, Sylvia Villeneuve, Jakub Hort, Stephane Epelbaum, Alberto Lleo, Sebastiaan Engelborghs, Wiesje M. van der Flier, Susan Landau, Julius Popp, Anders Wallin, Philip Scheltens, Marcel Olde Rikkert, Peter J. Snyder, Chris Rowe, Gael Chetelat, Agustin Ruiz, Marta Marquie, Elena Chipi, Steffen Wolfsgruber, Michael Heneka, Henning Boecker, Oliver Peters, Jonas Jarholm, Lorena Rami, Adria Tort-Merino, Alexa Pichet Binette, Judes Poirier, Pedro Rosa-Neto, Jiri Cerman, Bruno Dubois, Marc Teichmann, Daniel Alcolea, Juan Fortea, M. Belen Sanchez-Saudinos, Jarith Ebenau, Cornelia Pocnet, Marie Eckerstrom, Louisa Thompson, Victor Villemagne, Rachel Buckley, Samantha Burnham, Marion Delarue, Yvonne Freund-Levi, Asa K. Wallin, Inez Ramakers, Magda Tsolaki, Hilkka Soininen, Harald Hampel, Luiza Spiru, Betty Tijms, Rik Ossenkoppele, Frans R. J. Verhey, Frank Jessen, Pieter Jelle Visser
Summary: In addition to age, setting, and APOE ε4 carriership, specific characteristics of subjective cognitive decline may aid in identifying individuals with amyloid positivity.
ALZHEIMERS & DEMENTIA
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Vincent Dore, Natasha Krishnadas, Pierrick Bourgeat, Kun Huang, Shenpeng Li, Samantha Burnham, Colin L. Masters, Jurgen Fripp, Victor L. Villemagne, Christopher C. Rowe
Summary: The study found that Aβ levels between 10 and 40 CL are associated with spreading of tau protein in different brain regions, and abnormal levels of tau protein in the neocortex require Aβ levels above 40 CL. The highest prevalence of abnormal tau protein was found in the entorhinal cortex.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Medicine, General & Internal
Laia Montoliu-Gaya, Andre Strydom, Kaj Blennow, Henrik Zetterberg, Nicholas James Ashton
Summary: Epidemiological evidence suggests that individuals with Down syndrome may develop Alzheimer's disease neuropathology by the age of 40. Diagnosis of dementia in these patients is challenging due to pre-existing intellectual disabilities. Blood biomarkers are seen as a promising tool for AD diagnosis in this vulnerable population.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Zohreh Mohammadi, Hadi Alizadeh, Janos Marton, Paul Cumming
Summary: Hyperphosphorylated tau aggregates are characteristic features of Alzheimer's disease (AD). The development of molecular imaging of tau by positron emission tomography (PET) started with [F-18]FDDNP, which had off-target binding to tau and obtained regional specificity through the distribution of amyloid beta and tau in AD brains. Several tau PET tracers have been developed, with F-18-flortaucipir being the first approved by the FDA. These tracers differ in selectivity, off-target binding, and uptake in white matter. In this review, the binding properties of the tracers in vitro and their effectiveness in discriminating between AD patients and healthy controls were compared. The available tracers showed good discrimination, with higher effectiveness in more severe AD patients.
Article
Clinical Neurology
Hana Florian, Deli Wang, Steven E. Arnold, Merce Boada, Qi Guo, Ziyi Jin, Hui Zheng, Nahome Fisseha, Hari Varun Kalluri, Beatrice Rendenbach-Mueller, Kumar Budur, Michael Gold, Thomas Aware Investigators, Lealani Acosta, Thomas Ala, Sanka Amadoru, Jeffrey Apter, Steven Arnold, Merce Boada-Rovira, Anne Boerjesson-Hanson, Wendy Bond, Michael Borrie, Gabriella Bottini, Bruce Brew, Mark Brody, James Burke, Jeffrey Burns, Annalisa Chiari, Roger Clarnette, Sharon Cohen, Martin Farlow, Simon Fishman, Norman Foster, Kristian Frederiksen, Giovanni Frisoni, Nigel Gilchrist, Darren Gitelman, Ira Goodman, Marc Gordon, Neill Graff-Radford, Merja Hallikainen, Adrian Ivanoiu, Gregory Jicha, Michael Jonsson, Diana Kerwin, Dineke Koek, James Lah, Ayesha Lall, Elly Lee, Gabriel Leger, Peter Ljubenkov, Camillo Marra, Pablo Martinez-Lage, Joseph Masdeu, Scott McGinnis, Patrizia Mecocci, Philip Morris, Marshall Nash, Allison Perrin, Aimee Pierce, Robert Riesenberg, Juha Rinne, Raquel Sanchez Del Valle, Elio Scarpini, Paul Schulz, Ronald Schwartz, Amanda Smith, Bryan Spann, Sylvie Van Snick, Rik Vandenberghe, Cherian Verghese, Alberto Villarejo, Chuang-Kuo Wu
Summary: Tau accumulation in patients with Alzheimer's disease is closely related to cognitive decline. This study evaluated tilavonemab, an anti-tau monoclonal antibody, in treating patients with early Alzheimer's disease. The results showed that tilavonemab did not demonstrate efficacy in treating early Alzheimer's disease.
Article
Clinical Neurology
Shorena Janelidze, Divya Bali, Nicholas J. Ashton, Nicolas R. Barthelemy, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, Yingxin He, Anna Orduna Dolado, Gallen Triana-Baltzer, Michael J. Pontecorvo, Henrik Zetterberg, Hartmuth Kolb, Manu Vandijck, Kaj Blennow, Randall J. Bateman, Oskar Hansson
Summary: Plasma phospho-tau species, especially p-tau217, show promise as blood-based biomarkers for Alzheimer's disease. This study compared the performance of different assays for p-tau181, p-tau217, and p-tau231 in detecting abnormal A beta status and predicting progression to Alzheimer's dementia. The mass spectrometry-based p-tau217 (p-tau217(WashU)) demonstrated the best performance, while several immunoassays, including p-tau217(Lilly), p-tau217(Janss), p-tau181(ADx), and p-tau181(WashU), showed high accuracy in both outcomes.
Article
Clinical Neurology
Nicholas J. Ashton, Albert Puig-Pijoan, Marta Mila-Aloma, Aida Fernandez-Lebrero, Greta Garcia-Escobar, Fernando Gonzalez-Ortiz, Przemyslaw R. Kac, Wagner S. Brum, Andrea L. Benedet, Juan Lantero-Rodriguez, Theresa A. Day, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, Gallen Triana-Baltzer, Setareh Moughadam, Hartmuth Kolb, Paula Ortiz-Romero, Thomas K. Karikari, Carolina Minguillon, Juan Jose Hernandez Sanchez, Irene Navalpotro-Gomez, Oriol Grau-Rivera, Rosa Maria Manero, Victor Puente-Periz, Rafael de la Torre, Jaume Roquer, Jeff L. Dage, Henrik Zetterberg, Kaj Blennow, Marc Suarez-Calvet
Summary: This study compared the main blood phosphorylated tau immunoassays in a memory clinic population and found that several plasma p-tau biomarkers can be used as stand-alone biomarkers to detect Alzheimer's disease.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Ying Meng, Maged Goubran, Jennifer S. Rabin, Melissa McSweeney, Julie Ottoy, Christopher B. Pople, Yuexi Huang, Alexandra Storace, Miracle Ozzoude, Allison Bethune, Benjamin Lam, Walter Swardfager, Chinthaka Heyn, Agessandro Abrahao, Benjamin Davidson, Clement Hamani, Isabelle Aubert, Henrik Zetterberg, Nicholas J. Ashton, Thomas K. Karikari, Kaj Blennow, Sandra E. Black, Kullervo Hynynen, Nir Lipsman
Summary: In this study, the researchers investigated the feasibility and tolerability of opening the blood-brain barrier in the default mode network using MR-guided focused ultrasound in patients with Alzheimer's disease. The intervention resulted in a reduction of local amyloid in PET imaging, but had no effect on disease-specific markers in plasma or CSF. The study highlights the importance of understanding the impact of blood-brain barrier modulation on neurodegenerative diseases and its potential for therapeutic delivery.
Review
Clinical Neurology
Lyduine E. Collij, Gill Farrar, David Vallez Garcia, Ilona Bader, Mahnaz Shekari, Luigi Lorenzini, Hugh Pemberton, Daniele Altomare, Sandra Pla, Mery Loor, Pawel Markiewicz, Maqsood Yaqub, Christopher Buckley, Giovanni B. Frisoni, Agneta Nordberg, Pierre Payoux, Andrew Stephens, Rossella Gismondi, Pieter Jelle Visser, Lisa Ford, Mark Schmidt, Cindy Birck, Jean Georges, Anja Mett, Zuzana Walker, Merce Boada, Alexander Drzezga, Rik Vandenberghe, Bernard Hanseeuw, Frank Jessen, Michael Scholl, Craig Ritchie, Isadora Lopes Alves, Juan Domingo Gispert, Frederik Barkhof, AMYPAD Consortium
Summary: Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium aims to provide evidence on the clinical utility and cost-effectiveness of Positron Emission Tomography (PET) imaging in AD diagnosis and support clinical trial design. AMYPAD has contributed significantly to understanding of amyloid deposition in the brain and improving measurement methodology. Future steps include integrating and curating available clinical data for wider scientific access.
FRONTIERS IN NEUROLOGY
(2023)
Article
Medicine, General & Internal
Camilla Caprioglio, Federica Ribaldi, Leonie N. C. Visser, Carolina Minguillon, Lyduine E. Collij, Oriol Grau-Rivera, Philip Zeyen, Jose Luis Molinuevo, Juan Domingo Gispert, Valentina Garibotto, Christian Moro, Zuzana Walker, Paul Edison, Jean-Francois Demonet, Frederik Barkhof, Philip Scheltens, Isadora Lopes Alves, Rossella Gismondi, Gill Farrar, Andrew W. Stephens, Frank Jessen, Giovanni B. Frisoni, Daniele Altomare
Summary: Individuals who are amyloid-positive with subjective cognitive decline (SCD+) are at higher risk of developing dementia. The disclosure of a positive amyloid-PET result might have psychological risks, but such change did not reach the threshold for clinical concern.
Article
Clinical Neurology
Daniele Altomare, Sara Stampacchia, Federica Ribaldi, Szymon Tomczyk, Claire Chevalier, Geraldine Poulain, Saina Asadi, Bianca Bancila, Moira Marizzoni, Marta Martins, Aurelien Lathuiliere, Max Scheffler, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Ilse Kern, Miguel Frias, Valentina Garibotto, Giovanni B. Frisoni
Summary: This study aimed to confirm the correlations between plasma and traditional Alzheimer's disease (AD) biomarkers, assess the diagnostic accuracy of plasma biomarkers compared to traditional biomarkers, and estimate the potential savings in traditional exams by using plasma biomarkers. The results showed significant correlations between plasma biomarkers and traditional biomarkers, and high accuracy in discriminating biomarker status. The implementation of plasma biomarkers could save a significant proportion of expensive traditional exams, making the diagnostic workup more cost-effective and improving patient care.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Biochemistry & Molecular Biology
Krystian Lazowski, Mahmood Faraz, Alexandra Vaisman, Nicholas W. Ashton, Piotr Jonczyk, Iwona J. Fijalkowska, Anders R. Clausen, Roger Woodgate, Karolina Makiela-Dzbenska
Summary: In Escherichia coli, replication of genomic DNA is mainly carried out by DNA polymerase III holoenzyme (pol III HE). However, in certain genetic backgrounds, DNA polymerase V (pol V) can access undamaged genomic DNA and cause increased spontaneous mutagenesis on the lagging strand. This study investigates the repair of ribonucleotides on both DNA strands in E. coli using active site mutants of pol III and pol V. The findings suggest unequal repair of ribonucleotides, with different repair systems involved in the leading and lagging strands.
NUCLEIC ACIDS RESEARCH
(2023)
Article
Multidisciplinary Sciences
Joao Pedro Ferrari-Souza, Firoza Z. Lussier, Douglas T. Leffa, Joseph Therriault, Cecile Tissot, Bruna Bellaver, Pamela C. L. Ferreira, Maura Malpetti, Yi-Ting Wang, Guilherme Povala, Andrea L. Benedet, Nicholas J. Ashton, Mira Chamoun, Stijn Servaes, Gleb Bezgin, Min Su Kang, Jenna Stevenson, Nesrine Rahmouni, Vanessa Pallen, Nina Margherita Poltronetti, John T. O'Brlen, James B. Rowe, Ann D. Cohen, Oscar L. Lopez, Dana L. Tudorascu, Thomas K. Karikari, William E. Klunk, Victor L. Villemagne, Jean-Paul Soucy, Serge Gauthier, Diogo O. Souza, Henrik Zetterberg, Kaj Blennow, Eduardo R. Zimmer, Pedro Rosa-Neto, Tharick A. Pascoal
Summary: Animal studies indicate that the APOE epsilon 4 allele is associated with early microglial activation in Alzheimer's disease (AD). In this study, the association between APOE epsilon 4 status and microglial activation in living individuals was examined. The results showed that APOE epsilon 4 carriers exhibited higher levels of microglial activation in early Braak stage regions within the medial temporal cortex, which was linked to A beta and tau deposition. Furthermore, the activation of microglia mediated the A beta-independent effects of APOE epsilon 4 on tau accumulation, leading to neurodegeneration and clinical impairment. The findings suggest that APOE epsilon 4 genotype plays a role in AD pathogenesis by activating microglia in brain regions associated with early tau deposition.
Article
Medicine, General & Internal
Laia Montoliu-Gaya, Daniel Alcolea, Nicholas J. Ashton, Jordi Pegueroles, Johannes Levin, Beatriz Bosch, Juan Lantero-Rodriguez, Maria Carmona-Iragui, Olivia Wagemann, Mircea Balasa, Przemyslaw Radoslaw Kac, Isabel Barroeta, Albert Llado, Wagner S. Brum, Laura Videla, Fernando Gonzalez-Ortiz, Bessy Benejam, Javier Jose Arranz Martinez, Thomas K. Karikari, Georg Nuebling, Alexandre Bejanin, Andrea L. Benedet, Rafael Blesa, Alberto Lleo, Kaj Blennow, Raquel Sanchez-Valle, Henrik Zetterberg, Juan Fortea
Summary: This study found that plasma GFAP levels are associated with the diagnosis and progression of Alzheimer's disease in adults with Down syndrome, indicating its potential as a biomarker. This biomarker may have applications in clinical practice and clinical trials.
Editorial Material
Neurosciences
Michael Scholl
BRAIN CONNECTIVITY
(2023)
Article
Clinical Neurology
Anita L. Sunde, Ingvild V. Alsnes, Dag Aarsland, Nicholas J. Ashton, Diego A. Tovar-Rios, Giovanni De Santis, Kaj Blennow, Henrik Zetterberg, Svein R. Kjosavik
Summary: This study found that plasma storage duration and temperature do not affect the concentrations of Alzheimer's disease biomarkers. The plasma samples can be stored at +4 degrees C or +18 degrees C for 24 hours without impacting the assay results for p-tau181, p-tau231, A beta 42/A beta 40 ratio, GFAP, and NfL.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
(2023)
Article
Clinical Neurology
Wiesje Pelkmans, Mahnaz Shekari, Anna Brugulat-Serrat, Gonzalo Sanchez-Benavides, Carolina Minguillon, Karine Fauria, Jose Luis Molinuevo, Oriol Grau-Rivera, Armand Gonzalez Escalante, Gwendlyn Kollmorgen, Margherita Carboni, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Marc Suarez-Calvet, Juan Domingo Gispert
Summary: We studied the role of biomarkers of reactive astrogliosis in the pathogenic cascade of Alzheimer's disease. Various fluid biomarkers were found to influence the progression of the disease, with GFAP mediating the association between soluble and insoluble Aβ, and YKL-40 partly explaining the association between Aβ and downstream tau pathology and neuronal injury.
ALZHEIMERS & DEMENTIA
(2023)
Article
Biochemistry & Molecular Biology
Nicholas W. Ashton, Nancy Jaiswal, Natalia Cestari Moreno, Irina Semenova, Dana A. D'Orlando, Marcela Teatin Latancia, Justyna McIntyre, Roger Woodgate, Irina Bezsonova
Summary: This study identified a novel interaction between Y-family DNA polymerases and the nucleotide excision repair proteins RAD23A and RAD23B. The authors found that RAD23A's ubiquitin-binding domains interact with separate sites within the catalytic domain of Pol 1, and both interactions are necessary for stable binding. They also discovered that RAD23 proteins interact with Y-family polymerases in a similar manner.
JOURNAL OF MOLECULAR BIOLOGY
(2023)
Article
Medicine, General & Internal
Fernando Gonzalez-Ortiz, Maciej Dulewicz, Nicholas J. Ashton, Przemyslaw R. Kac, Henrik Zetterberg, Emma Andersson, Yara Yakoub, Jorg Hanrieder, Michael Turton, Peter Harrison, Bengt Nellgard, Thomas K. Karikari, Kaj Blennow
Summary: This study suggests that serum BD-tau, T-tau, and p-tau(231) have differential associations with clinical outcome and 1-year longitudinal change in patients with sTBI. Serum BD-tau demonstrated utility as a biomarker to monitor outcomes in sTBI and can provide valuable information regarding acute neuronal damage.
Article
Clinical Neurology
William Coath, Marc Modat, M. Jorge J. Cardoso, Pawel J. A. Markiewicz, Christopher A. D. Lane, Thomas D. Parker, Ashvini M. Keshavan, Sarah M. E. Buchanan, Sarah E. J. Keuss, Matthew J. Harris, Ninon Burgos, John Dickson, Anna L. Barnes, David L. Thomas, Daniel B. Beasley, Ian B. Malone, Andrew Wong, Kjell A. Erlandsson, Benjamin A. Thomas, Michael Scholl, Sebastien Ourselin, Marcus C. Richards, Nick C. M. Fox, Jonathan M. M. Schott, David M. Cash
Summary: The Centiloid scale aims to harmonize Aβ PET measures across different analysis methods. This study investigated the Centiloid transformation with PET/MRI data, finding that the transformation is valid but further understanding of the effects of acquisition or biological factors on using white matter as a reference is needed.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
(2023)
Review
Neurosciences
Maya Jammoul, Dareen Jammoul, Kevin K. Wang, Firas Kobeissy, Ralph G. Depalma
Summary: This article reviews the possible mechanisms by which traumatic brain injury (TBI) may stimulate the development of opioid use disorder (OUD) and discusses the interaction between these two processes. CNS damage due to TBI appears to drive adverse effects of subsequent OUD, with pain being a risk factor for opioid use after TBI.
BIOLOGICAL PSYCHIATRY
(2024)
Article
Neurosciences
Danusa Mar Arcego, Jan-Paul Buschdorf, Nicholas O'Toole, Zihan Wang, Barbara Barth, Irina Pokhvisneva, Nirmala Arul Rayan, Sachin Patel, Euclides Jose de Mendonca Filho, Patrick Lee, Jennifer Tan, Ming Xuan Koh, Chu Ming Sim, Carine Parent, Randriely Merscher Sobreira de Lima, Andrew Clappison, Kieran J. O'Donnell, Carla Dalmaz, Janine Arloth, Nadine Provencal, Elisabeth B. Binder, Josie Diorio, Patricia Pelufo Silveira, Michael J. Meaney
Summary: This study investigates the impact of environmental influences on mental health by integrating transcriptomic data from animal models with human data. The results suggest that hippocampal glucocorticoid-related transcriptional activity mediates the effects of early adversity on neural mechanisms implicated in psychiatric disorders.
BIOLOGICAL PSYCHIATRY
(2024)
Article
Neurosciences
Milenna T. van Dijk, Ardesheer Talati, Pratik Kashyap, Karan Desai, Nora C. Kelsall, Marc J. Gameroff, Natalie Aw, Eyal Abraham, Breda Cullen, Jiook Cha, Christoph Anacker, Myrna M. Weissman, Jonathan Posner
Summary: This study found that maternal stress is associated with future depressive symptoms and alterations in microstructure of the dentate gyrus (DG) in offspring. These results were consistent across two independent cohorts.
BIOLOGICAL PSYCHIATRY
(2024)
Article
Neurosciences
Josephine C. McGowan, Liliana R. Ladner, Claire X. Shubeck, Juliana Tapia, Christina T. LaGamma, Amanda Anqueira-Gonzalez, Ariana DeFrancesco, Briana K. Chen, Holly C. Hunsberger, Ezra J. Sydnor, Ryan W. Logan, Tzong-Shiue Yu, Steven G. Kernie, Christine A. Denny
Summary: Traumatic brain injury (TBI) leads to fear generalization by altering fear memory traces, and this symptom can be improved with (R,S)-ketamine.
BIOLOGICAL PSYCHIATRY
(2024)